The Zenith Building, Tower A
Suite 1902 Level 19 821 Pacific Highway
Chatswood, NSW 2067
61 2 8607 5126
Industry: Drug Manufacturers—Specialty & Generic
|Ms. Judith Mitchell M.B.A.||MD, CEO & Exec. Director||288.08k||N/A||N/A|
|Dr. Matthew Franco Myntti||Founder & CTO||366.61k||N/A||N/A|
|Ms. Jacqueline Butler CA (ICAEW)||Chief Financial Officer||267.91k||N/A||N/A|
|Mr. Jon Swanson||Chief Operating Officer||265.18k||N/A||N/A|
|Mr. Martyn Jacobs||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD||Company Sec.||N/A||N/A||N/A|
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.
Next Science Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.